Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Sysmex Inostics, Genomic Testing Cooperative partnership

May 2023—Sysmex Inostics and Genomic Testing Cooperative formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services, including Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services, to biopharma customers. The partnership brings together GTC’s proprietary genomic databases, technology in artificial intelligence, and DNA and RNA next-generation sequencing profiling with Sysmex Inostics’ worldwide commercial capabilities in biopharma therapeutic development and its Plasma-Safe-SeqS technology.

Tempus gets FDA approval for xT CDx

May 2023—Tempus announced that the FDA has approved the company’s premarket approval application for its companion diagnostic test, xT CDx, to identify patients who may benefit from treatment with the targeted therapies listed in the product’s indications for use. It is a qualitative next-generation sequencing–based in vitro diagnostic device for use in the detection of single nucleotide variants, multi-nucleotide variants, and insertion and deletion alterations in 648 genes and includes the evaluation of microsatellite instability.

Verichem calibration verifiers, reference materials

May 2023—Verichem Laboratories now offers multilevel calibration verification materials for amylase and lipase activity as part of its liquid-stable, ready-to-use Enzyme ER Verifier kit. The product is for use on automated chemistry systems and has a shelf life of 18 months. The kit contains one 5-mL dropper vial for each of the six levels.

Quest to acquire Haystack Oncology

May 2023—Quest Diagnostics and Haystack Oncology, an early-stage oncology company focused on minimal residual disease testing, announced on April 27 a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.

Illumina launches Connected Insights software

May 2023—Illumina announced the release of Connected Insights, a cloud-based software for tertiary analysis of clinical next-generation sequencing data. The software enables labs to connect to a network of more than 45 third-party knowledge sources that provide digital directories for precision oncology, illustrating connections between cancer variants and therapies, citing evidence, and aiding analysis of complex cancer genomic profiles. It can also link users to regional guidelines, clinical trial databases, drug labels, and a private collection of data from previous cases within a customer’s laboratory. As the use of clinical NGS testing grows, Illumina says it will expand the software’s capabilities across other disease areas.

 

QuidelOrtho gets de novo authorization for Sofia 2 SARS Antigen+ FIA

May 2023—QuidelOrtho Corp. has been granted a de novo request from the FDA for its new Sofia 2 SARS Antigen+ FIA, a lateral flow immunofluorescent assay that is used with the Sofia 2 fluorescent immunoassay analyzer. It is intended for the qualitative detection of the nucleocapsid protein antigen of SARS-CoV-2 in direct anterior nasal swab specimens from people with signs and symptoms of upper respiratory infection when serial testing is started within six days of symptom onset. The Sofia 2 analyzer provides a result in 10 minutes.

Tissue‑Tek block filing cabinet

May 2023—Sakura Finetek has launched its Tissue‑Tek Block Filing Cabinet 2400, which has six drawers and a capacity of 2,400 paraffin-embedded tissue blocks.

Maine Molecular releases SpotFire RSP controls

May 2023—Maine Molecular Quality Controls has released SpotFire RSP positive and RSP negative controls. The quality controls are for use in monitoring the performance of in vitro laboratory nucleic acid testing for the qualitative detection of Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae, adenovirus, seasonal coronavirus, SARS-CoV-2, human metapneumovirus, human rhinovirus/enterovirus, influenza A subtypes H1-2009 and H3, influenza B, parainfluenza virus, and RSV.

BioGx Candida auris PCR assay adoption accelerates

April 2023—BioGx announced accelerated adoption of its high-performance Sample-Ready PCR assay for the detection of Candida auris. A complete PCR mix is provided in a single lyophilized tube format to be validated by laboratories on a variety of real-time PCR instruments, including the BD Max, Thermo Fisher QuantStudio, Bio-Rad CFX Touch, and BioGx Pixl platform. The company says its assay has been successfully validated and implemented by public health laboratories and hospitals in several states.

 

MARKETPLACE

TRENDING